<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[vyvanse Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/vyvanse.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to vyvanse]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[The Pfizer-Shire Deal Worst-Case Scenario]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000569/the-pfizer-shire-deal-worst-case-scenario/]]></link>
		<description><![CDATA[Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 Jan 2009 14:00:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/medicaid.html"><![CDATA[Medicaid]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/adhd.html"><![CDATA[ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/barr.html"><![CDATA[Barr]]></category>
		<category domain="http://resources.bnet.com/topic/cola.html"><![CDATA[Cola]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Our Favorite Drug Company Conference Call Tap Dancers]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000389/our-favorite-drug-company-conference-call-tap-dancers/]]></link>
		<description><![CDATA[Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 13 Nov 2008 18:03:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/operating+margin.html"><![CDATA[Operating Margin]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/operating+margin.html"><![CDATA[Operating Margin]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire's Big Gamble on ADHD Drug Vyvanse]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000202/shires-big-gamble-on-adhd-drug-vyvanse/]]></link>
		<description><![CDATA[One of the recent unheralded successes of the drug world was Shire Pharmaceuticals' launch of Vyvanse, a new, long-acting treatment for attention deficit and hyperactivity disorder. The fact that so little attention has been paid to Vyvanse is a shame because the take-up of this drug has been impressive --...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Sep 2008 09:03:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/generic.html"><![CDATA[Generic]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[Vyvanse]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi.html"><![CDATA[Sanofi]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[SHIRE PLC - FDA Approval of prodrug VYVANSE for treatment of ADHD.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200702/ai_n23963266]]></link>
		<description><![CDATA[Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only  Stimulant Prodrug VYVANSEao lisdexamfetamine dimesylate as a Novel Treatment  for ADHD    Basingstoke, U.K., Philadelphia, PA and Radford, VA - FEBRUARY 23, 2007 - Shire  plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ)...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 26 Feb 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/readers.html"><![CDATA[Readers]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[VYVANSE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200612/ai_n23588404]]></link>
		<description><![CDATA[BASINGSTOKE, England, PHILADELPHIA and RADFORD, Virginia, December  22 /PRNewswire/ --    - Launch Expected Q2 2007    New River Pharmaceuticals Inc. (Nasdaq: NRPH) and its collaborative  partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today  that the U.S. Food and Drug...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 22 Dec 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/readers.html"><![CDATA[Readers]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/vyvanse.html"><![CDATA[VYVANSE]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
